Updated Management of Ulcerative Colitis

Authors

  • Muhamad Reza Prabowo Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo General National Hospital, Jakarta
  • Achmad Fauzi Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo General National Hospital, Jakarta

DOI:

https://doi.org/10.24871/2622025160-167

Keywords:

Anti-integrin, biologic agent, management, small molecules, ulcerative colitis

Abstract

Ulcerative Colitis (UC) is a chronic disorder of Inflammatory Bowel Disease (IBD) which showed pathological changes of mucosa (symmetrical, diffuse) that involving rectum and may be extended to proximal colon. In general, target of the treatment quite indistinguishable to Crohn’s Disease (CD), such as improving quality of life, treating the acute condition, maintaining remission status, preventing complications, and achieving adequate nutritional status. Nowadays, there are so many therapeutic agents which were more effective than previous drugs. Another reason we should have left prior medicine is the safety of newer agents are promising. Today’s technology advances make gastroenterologist easier to give more treatment choice to every spectrum of ulcerative colitis. This review aims to provide an updated overview of ulcerative colitis management.

References

Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc. 2017;92(7):1088-103.

Cushing K, Higgins PDR. Management of Crohn disease: a review. JAMA. 2021 Jan 5;325(1):69-80.

Majewska K, Rusinowski C, Jablonska B, Golka D, Mrowlec S. Retrospective study of surgical outcomes in 60 patients with Crohn disease from a single center in Poland. Med Sci Monit. 2022;28:e934463.

Luglio G, Cassese G, Amendola A, Rispo A, Maione F, De Palma GD. Novel approaches to ileocolic and perianal fistulising Crohn’s disease. Gastroenterol Res Pract. 2018;2018:3159543.

Rubbino F, Greco L, Di Cristofaro A, Gaiani F, Vetrano S, Laghi L, et al. Journey through Crohn’s disease complication: from fistula formation to future therapies. J Clin Med. 2021;10(23):5548.

Haas M, Treton X, Stefanescu C, Bouhnik Y. Intra-abdominal abscesses in Crohn’s disease – when to treat with biologics? United European Gastroenterol J. 2022;10:1085-90.

Tadesse R, Ewnte B, Tesfaye K. Perforated ileum as the initial presentation of Crohn’s disease: a case report. Int J Surg Case Rep. 2022;97:107305.

Richards RJ. Management of abdominal and pelvic abscess in Crohn’s disease. World J Gastrointest Endosc. 2011 Nov 16;3(11):209-12.

Kayar Y, Baran B, Ormeci AC, Akyuz F, Demir K, Besisik F, et al. Risk factors associated with progression to intestinal complications of Crohn disease. Chin Med J (Engl). 2019;132(20):2423-9.

Carvalho ATP, Esberard BC, Moreira AL. Current management of spontaneous intra-abdominal abscess in Crohn’s disease. J Coloproctol (Rio J). 2016. Available from: http://dx.doi.org/10.1016/j.jcol.2016.05.003

Feagins LA, Holubar SD, Kane SV, Spechler SJ. Current strategies in the management of intra-abdominal abscesses in Crohn’s disease. Clin Gastroenterol Hepatol. 2011 Oct;9(10):842-50.

De Groof EJ, Carbonnel F, Buskens CJ, Bemelman WA. Abdominal abscess in Crohn’s disease: multidisciplinary management. Dig Dis. 2014;32(Suppl 1):103-9.

Waked B, Holvoet T, Geldof J, Baert F, Pattyn P, Lobaton T, et al. Conservative management of spontaneous intra-abdominal abscess in Crohn’s disease: outcome and prognostic factors. J Dig Dis. 2021 May;22(5):263-70.

Pal P, Kanaganti S, Banerjee R, Ramchandani M, Nabi Z, Reddy DN, et al. Systematic review of endoscopic management of stricture, fistula and abscess in inflammatory bowel disease. Gastroenterol Insights. 2023;14(1):45-63.

Shen B. Interventional inflammatory bowel disease: endoscopic therapy of complications of Crohn’s disease. Gastroenterol Rep (Oxf). 2022;10:goac045.

Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, et al. A comprehensive review and update on Crohn’s disease. Dis Mon. 2018;64(2):20-57.

Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, et al. Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe Crohn’s disease: real-world experience from a multicenter cohort study. Inflamm Bowel Dis. 2017;23(5):833-9.

Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterol. 2016;7(4):289-300.

Lee YW, Lee KM, Kim JY, Ryu JK, Lee SH, Yoon YB, et al. Clinical outcomes of percutaneous drainage of abdominal abscesses in Crohn’s disease. J Korean Med Sci. 2010;25(4):636-42.

Lee H, Park SH, Kim SY, Lee HS, Choi SI, Lee JH, et al. Percutaneous drainage versus surgery for abdominal abscess in patients with Crohn’s disease: nationwide population-based study. J Gastroenterol Hepatol. 2020;35(6):971-8.

Clancy C, Boland T, Deasy J, McNamara D, Burke JP. A meta-analysis of percutaneous drainage versus surgery as the initial treatment of Crohn’s disease-related intra-abdominal abscess. J Crohns Colitis. 2016;10(2):202-8.

Zerbib P, Koriche D, Truant S, Bouras AF, Vernier-Massouille G, Seguy D, et al. Pre-operative management is associated with low rate of post-operative recurrence in Crohn’s disease. Colorectal Dis. 2010;12(12):1131-8.

Yamaguchi A, Matsui T, Sakurai T, Ueki M, Nakabayashi S, Yao T, et al. The clinical characteristics and outcome of intraabdominal abscess in Crohn’s disease. J Gastroenterol. 2004;39(5):441-8.

Greener T, Kabakchiev B, Steinhart AH, Silverberg MS. Clinical predictors of response to medical therapy in patients with intra-abdominal fistulizing Crohn’s disease. Inflamm Bowel Dis. 2015;21(8):1835-41.

Yamamoto T, Keighley MRB. Enterocutaneous fistulas complicating Crohn’s disease: clinicopathological features and management. Int J Colorectal Dis. 2000;15(4):211-5.

Topstad DR, Panaccione R, Heitman SJ, Kaplan GG, Ghosh S, Hubbard JG, et al. Nonoperative management of intra-abdominal abscesses complicating Crohn’s disease. Dis Colon Rectum. 2006;49(7):970-5.

Nguyen DL, Bechtold ML, Jamal MM. Outcomes of nonoperative management for intra-abdominal abscesses in patients with Crohn’s disease: a systematic review and meta-analysis. Saudi J Gastroenterol. 2013;19(4):163-9.

Ayoub F, Liron R, Bhat A, Schwartz D, Marano R, Brathwaite C, et al. Nonoperative management of spontaneous intra-abdominal abscesses in Crohn’s disease: predictors of outcome. Am Surg. 2016;82(6):511-5.

Kwon JH, Kim HJ, Han DS, Kim YH, Lee J, Choi KY, et al. Long-term outcomes of percutaneous drainage versus surgery for intra-abdominal abscess in Crohn’s disease: a multicenter retrospective study. Intest Res. 2014;12(4):281-8.

El-Hussuna A, Andersen J, Bisgaard T, Olaison G, Stocchi L, Gogenur I, et al. Biologics before surgery reduce recurrence after surgery for Crohn’s disease: a systematic review and meta-analysis. J Crohns Colitis. 2014;8(9):867-79.

Lee HS, Park SH, Kim SY, Kim YH, Kim TI, Kim WH, et al. Clinical outcomes of early surgery versus prolonged medical therapy for intra-abdominal abscess in Crohn’s disease. Dig Dis Sci. 2012;57(10):2591-6.

Geltzeiler CB, Hart KD, Lu KC, Deveney KE, Herzig DO, Tsikitis VL. Trends in the surgical management of Crohn’s disease. J Gastrointest Surg. 2015;19(10):1862-8.

Riss S, Schuster I, Papay P, Mittlböck M, Stift A. Surgical recurrence after primary ileocolic resection for Crohn’s disease. Tech Coloproctol. 2014;18(4):365-71.

Sica GS, Di Carlo S, Tema G, Iaculli E, Faticanti Scucchi L, Gentileschi P, et al. Surgery for Crohn’s disease in the biologic therapy era. World J Gastroenterol. 2016;22(4):1394-403.

Yamamoto T. Factors affecting recurrence after surgery for Crohn’s disease. World J Gastroenterol. 2005;11(26):3971-9.

Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn’s disease. Ann Surg. 2000;231(1):38-45.

Downloads

Published

2025-08-15

How to Cite

Prabowo, M. R., & Fauzi, A. (2025). Updated Management of Ulcerative Colitis. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 26(2), 160–167. https://doi.org/10.24871/2622025160-167

Issue

Vol. 26 No. 2 (2025): VOLUME 26, NUMBER 2, August, 2025

Section

Review Article

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).